for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover Acta Radiologica Short Reports
   [3 followers]  Follow    
  This is an Open Access Journal Open Access journal
     ISSN (Print) 2047-9816 - ISSN (Online) 2047-9816
     Published by Sage Publications Homepage  [737 journals]
  • Tumor regression of multiple bone metastases from breast cancer after
           administration of strontium-89 chloride (Metastron)

    • Authors: Heianna, J; Miyauchi, T, Endo, W, Miura, N, Terui, K, Kamata, S, Hashimoto, M.
      Pages: 2047981613 - 2047981613
      Abstract: We report a case of tumor regression of multiple bone metastases from breast carcinoma after administration of strontium-89 chloride. This case suggests that strontium-89 chloride can not only relieve bone metastases pain not responsive to analgesics, but may also have a tumoricidal effect on bone metastases.
      PubDate: 2014-05-12T04:05:28-07:00
      DOI: 10.1177/2047981613493412|hwp:resource-id:sparr;3/4/2047981613493412
      Issue No: Vol. 3, No. 4 (2014)
  • An unusual case of primary hepatic lymphoma mimicking sarcoidosis in MRI

    • Authors: Do, T. D; Neurohr, C, Michl, M, Reiser, M. F, Zech, C. J.
      Pages: 2047981613 - 2047981613
      Abstract: Sarcoidosis is a granulomatous disease, in which liver affection is common, contrary to a primary hepatic lymphoma that is very rarely seen. On MRI both present with almost the same imaging features: hypointense in T1-weighted and hyperintense in T2-weighted sequences. Our patient with a histologically confirmed sarcoidosis in the lungs showed liver lesions that were similar to sarcoidosis manifestations of the liver. Due to size, progression and overlapping features with secondary malignant liver lesions within an interval of 5 months, a biopsy was conducted and confirmed a primary hepatic lymphoma with diffuse large b-cells. Thus, we would recommend performing a biopsy in ambiguous lesions with indistinguishable characteristics and progression within a short follow-up interval.
      PubDate: 2014-05-12T04:05:28-07:00
      DOI: 10.1177/2047981613493625|hwp:resource-id:sparr;3/4/2047981613493625
      Issue No: Vol. 3, No. 4 (2014)
  • Vertebral metastases from intracranial meningioma

    • Authors: Zaghouani, H; Yahyaoui, S, Chabchoub, I, Mallat, N, Majdoub, S, Amara, H, Bakir, D, Badreddine, S, Kraiem, C.
      Pages: 2047981613 - 2047981613
      Abstract: Meningioma rarely gives rise to metastases outside the brain and meninges. We report here a case of a patient who was treated for anaplastic brain meningioma with surgery and fractionated radiation therapy without any recurrence until 5 years after the operation, when she developed vertebral metastases.
      PubDate: 2014-05-12T04:05:28-07:00
      DOI: 10.1177/2047981613494199|hwp:resource-id:sparr;3/4/2047981613494199
      Issue No: Vol. 3, No. 4 (2014)
  • A longitudinal VBM study monitoring treatment with erythropoietin in
           patients with Friedreich ataxia

    • Authors: Santner, W; Schocke, M, Boesch, S, Nachbauer, W, Egger, K.
      Pages: 2047981614 - 2047981614
      Abstract: Background Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical improvement in rhuEPO treated patients with Friedreich ataxia (FRDA). Purpose To determine possible therapy dependent intracranial volume changes after treatment with rhuEPO using voxel-based morphometry (VBM). Material and Methods Nine FRDA patients were scanned on the same 1.5-Tesla MRI scanner before and after treatment with rhuEPO. FRDA patients received 5000 IU rhuEPO thrice weekly subcutaneously for a time period of 8 weeks followed by 2000 IU thrice weekly over 6 months. To test for re-test reliability a control group of 12 healthy volunteers were scanned twice on the same scanner without rhuEPO treatment. Neurological state was defined by the Friedreich Ataxia Rating Scale (FARS) and the Scale for the Assessment and Rating of Ataxia (SARA). Statistical parametric mapping software was used for image processing and statistical analysis. Results When comparing follow-up scans after rhuEPO treatment with baseline scans (P
      PubDate: 2014-05-12T04:05:28-07:00
      DOI: 10.1177/2047981614531573|hwp:resource-id:sparr;3/4/2047981614531573
      Issue No: Vol. 3, No. 4 (2014)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014